Targeted therapies that disrupt these interactions, such as monoclonal antibodies and small-molecule inhibitors, have shown significant clinical efficacy in treating HER2-driven malignancies such as HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.